K

Knight Therapeutics Inc
TSX:GUD

Watchlist Manager
Knight Therapeutics Inc
TSX:GUD
Watchlist
Price: 5.29 CAD -0.19% Market Closed
Market Cap: 534.2m CAD
Have any thoughts about
Knight Therapeutics Inc?
Write Note

Net Margin
Knight Therapeutics Inc

-8.8%
Current
-4%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-8.8%
=
Net Income
-30.7m
/
Revenue
348.6m

Net Margin Across Competitors

Country CA
Market Cap 534.2m CAD
Net Margin
-9%
Country JP
Market Cap 776 550.9T JPY
Net Margin
-79%
Country US
Market Cap 710.5B USD
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Net Margin
-4%
Country DK
Market Cap 3.3T DKK
Net Margin
35%
Country US
Market Cap 373.5B USD
Net Margin
17%
Country US
Market Cap 251.1B USD
Net Margin
19%
Country CH
Market Cap 202.7B CHF
Net Margin
20%
Country CH
Market Cap 183.3B CHF
Net Margin
35%
Country UK
Market Cap 162.4B GBP
Net Margin
13%
Country IE
Market Cap 146B USD
Net Margin
-126%
No Stocks Found

Knight Therapeutics Inc
Glance View

Market Cap
534.2m CAD
Industry
Pharmaceuticals

Knight Therapeutics Inc engages in acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. The company is headquartered in Montreal, Quebec and currently employs 660 full-time employees. The company went IPO on 2014-02-28. The firm's principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. The Company’s products include BIJUVA Estradiol and Progesterone capsule, IMVEXXY Estradiol vaginal inserts, IBSRELA Tenapanor tablets, TRELSTAR Prostate Triptorelin, TRELSTAR Endometriosis Triptorelin, ILUVIEN Fluocinolone acetonide, Nerlynx Neratinib Tablets, Nerlynx Patient Checklist, Nerlynx Prescriber Checklist, Burinex Bumetanide, Probuphine Buprenorphine implant, Movantik Naloxegol and Neuragen. The company owns Biotoscana Investments S.A., a pan-Latin American specialty pharmaceutical company. Its subsidiaries operates under United Medical, Biotoscana Farma and Laboratorio LKM.

GUD Intrinsic Value
6.31 CAD
Undervaluation 16%
Intrinsic Value
Price
K

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-8.8%
=
Net Income
-30.7m
/
Revenue
348.6m
What is the Net Margin of Knight Therapeutics Inc?

Based on Knight Therapeutics Inc's most recent financial statements, the company has Net Margin of -8.8%.